Novartis case in India

This page is under construction, please be patient as we develop it further

Background to the early development of IP in India.

Early pressure to change (marketing approval).

Accession to WTO and TRIPS.

Higher standards of patentability.

Waxman letter.

Petition

Decision that the new Glivec is not innovative.

Case brought by Novartis.

Political mobilisation around the issue.